

# Resistance testing for Third Line

Francesca Conradie

# Third-line ART

- Third-line ART is used when a patient has experienced virological failure on drugs from the NRTI, NNRTI and PI classes (with documented PI resistance).
- Adherence interventions should be intensified



SOUTHERN AFRICAN HIV CLINICIANS SOCIETY

# When to Use Resistance Testing

	IAS-USA <sup>[1]</sup>	DHHS <sup>[2]</sup>	European <sup>[3]</sup>
Primary/acute	Recommend	Recommend	Recommend
Postexposure prophylaxis			Recommend*
Chronic, Rx naive	Recommend	Recommend	Recommend
Failure	Recommend	Recommend	Recommend
Pregnancy	Recommend	Recommend	Recommend
Pediatric		Recommend	Recommend

\*Test source patient especially if treated with antiretroviral drugs.

1. Hirsch MS, et al. Clin Infect Dis. 2008;47:266-285.

2. November 2008 DHHS Guidelines. Available at: <http://www.aidsinfo.nih.gov>. Accessed November 10, 2008.

3. EACS Guidelines Version 3. Available at: <http://www.eacs.eu/guide/index.htm>. Accessed October 24, 2008.

# Southern African HIV Clinicians Society

## Failure of a boosted PI-based regimen

Adults and children with two VL measurements  $>1\ 000$  RNA copies/ml<sup>†</sup> and/or a  $<2\ \log_{10}$  drop in VL while on PI-based ART (measurements 3 - 6 months apart)

Recommended

Failure on PI regimens is almost always due to poor adherence. Adherence<sup>†</sup> issues should be addressed comprehensively between the 2 measurements. Resistance testing should be performed while the patient is on the failing regimen or within 4 weeks of discontinuation.

# What information can we get?

- Resistance tests serve two purposes:
  - Adherence test.
  - If resistance mutations are present, ability to chose a regimen.

# What information can we not get?

- NRTI mutations that are present only represent the current regimen.
  - Presume all first generations will not work
- NNRTI mutation are usually archived

# Requirements for resistance testing

- Patient must be on ART at the time or stopped within the last 4 weeks.
- Should not be done on the first detectable viral load
- No rush – between 3-6 months.

# Measures of adherence

- Self-reported, short-term adherence
- Dispensing-based long-term adherence
- Consistency of visit attendance
- Pill count-based medium-term adherence
- Electronic cap monitoring



# Adherence support

- Inadequate treatment literacy
- Side effects
- Depression and other mental illnesses
- Poverty and food insecurity
- Work related issues
- Substance use
- Social problems
- Denial
- Pill burden
- Altered fertility intentions
- Conflict of opinions


# Principles

- First-generation NNRTIs have no place in third-line therapy
- A boosted PI with the broadest resistance profile should be selected
- No double ritonavir-boosted PIs.
- The addition of 3TC (or FTC) is recommended
- Consideration of the addition of other salvage drugs (e.g. RAL and/or ETV) will depend on genotype resistance test result


## Patients who return after defaulting therapy

- Restart the same regimen and repeat HIV viral load measurements after 3 months
- Switching to a second-line regimen should be considered if the viral load is not suppressed at this point.
- AZT could be substituted for D4T.
- Do not substitute TDF

# Is VL < 50 copies/mL Achievable in Tx-Experienced Patients With MDR HIV?



- Consider emerging treatment options and need for immediate enhancement of current regimen (ie, risk of clinical progression)



- All effort should be made to address adherence problems
- “understand the failure”
- Once adherence problems are solved, resuppression is often possible under the same treatment.
- Request a Hep B sAg for patients failing a TDF based regimen. If Hepatitis B is positive, TDF should be included in the new regimen. (TDF is active against Hepatitis B virus)

# PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE

## Background:

- First-line ART for children < 3 years, PI + NRTI
- Children failing ritonavir or ritonavir-boosted lopinavir (LPV/r)
- Major PI resistance mutations (MPIRM)

# PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE

## Materials and Methods:

Pediatric HIV patients at Tygerberg Academic Hospital with virologic failure on a PI regimen.

Results: MPIRM were found in

12 of 17 patients exposed to RTV-sPI  
1 of 13 patients treated with LPV/r.

- Conclusions: RTV-sPI in infants and children poses a significant risk of MPIRM

- van Zyl, G.U. et al., 2009




**TABLE 1. Main Characteristics of Study Population**

Variable	LPV/r (n = 13)	RTV-sPI (n = 8)	RTV-sPI Followed by LPV/r (n = 9)	Total (n = 30)
Age at first study visit (mo)				
Median	27	20	33	28
Range	11–65	6–91	26–53	6–91
MPIRM (%)	1 (8%)	7 (88%)	5 (55%)	13 (43%)
Concurrent TB therapy (number [%])	5 (38%)	7 (88%)	7 (78%)	19 (63%)

LPV/r indicates Lopinavir co-formulated with low-dose ritonavir; RTV-sPI, RTV as single protease inhibitor; MPIRM, major protease inhibitor resistance mutations; TB, *Mycobacterium tuberculosis*.

van Zyl, G.U. et al., 2009. Protease inhibitor resistance in South African children with virologic failure. *The Pediatric infectious disease journal*, 28(12), pp.1125–7. 12, 2011].



- van Zyl, G.U. et al., 2009



HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.

- Viruses with resistance-associated mutations were isolated from 90% (95% CI 88-93%) of children.
- The prevalence of mutations associated with
  - NRTI - 80%,
  - NNRTI -88%
  - PI- 54%.

# Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Variable	Median (inter quartile range)		
	Median (inter quartile range)	No PI major mutations (n = 70)	PI major mutations (n = 5)
Age (years)	34 (29-40)		
CD4+ T-cells/mm <sup>3</sup>	141 (75-245)	138 (80-229)	246 (194-254)
HIV-1 RNA (copies/mL)	184,779 (8790-166,300)	61000 (15000-155000)	3260 (2200-33000)
Time on second-line (months)	16 (7-18)		

- Wallis, C.L. et al., 2011.

Resistance Mutations	n (%)
<i>NRTI mutations</i>	26 (35%)
M184V	15 (20%)
K65R	0 (0%)
Q151M	1 (1%)
TAMs	10 (13%)
<i>NNRTI mutations</i>	39 (52%)
K103N	16 (21%)
V106M	9 (12%)
<i>Any PR mutations (major and minor)</i>	67 (89%)
<i>MajorLPV mutations</i>	5 (7%)
M46I, L76V	1
M46I	1
L33F, I54S, V82A, I84V	1
L33F, M46I, I54V, I84V, L90M	1
M46I, I54V, L76V	1

- Major lopinavir resistance mutations were infrequent (5 of 75; 7%), indicating that drug resistance is not the main barrier to future viral suppression.

Wallis, C.L. et al., 2011. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. *AIDS research and treatment*, 2011, p.769627.